Department of Bioengineering, University of Utah, Salt Lake City, United States.
Department of Bioengineering, University of Utah, Salt Lake City, United States.
Biomaterials. 2018 Nov;183:67-76. doi: 10.1016/j.biomaterials.2018.08.039. Epub 2018 Aug 22.
Degradation of the extracellular matrix (ECM) is one of the fundamental factors contributing to a variety of life-threatening or disabling pathological conditions. However, a thorough understanding of the degradation mechanism and development of new ECM-targeting diagnostics are severely hindered by a lack of technologies for direct interrogation of the ECM structures at the molecular level. Previously we demonstrated that the collagen hybridizing peptide [CHP, sequence: (GPO), O: hydroxyproline] can specifically recognize the degraded and unfolded collagen chains through triple helix formation. Here we show that fluorescently labeled CHP robustly visualizes the pericellular matrix turnover caused by proteolytic migration of cancer cells within 3D collagen culture, without the use of synthetic fluorogenic matrices or genetically modified cells. To facilitate in vivo imaging, we modified the CHP sequence by replacing each proline with a (2S,4S)-4-fluoroproline (f) residue which interferes with the peptide's inherent propensity to self-assemble into homo-triple helices. We show that the new CHP, (GfO), tagged with a near-infrared fluorophore, enables in vivo imaging and semi-quantitative assessment of osteolytic bone lesions in mouse models of multiple myeloma. Compared to conventional techniques (e.g., micro-CT), CHP-based imaging is simple and versatile in vitro and in vivo. Therefore, we envision CHP's applications in broad biomedical contexts ranging from studies of ECM biology and drug efficiency to development of clinical molecular imaging.
细胞外基质(ECM)的降解是导致多种危及生命或使人丧失能力的病理状况的基本因素之一。然而,由于缺乏直接在分子水平上检测 ECM 结构的技术,对降解机制的深入了解和新的 ECM 靶向诊断的开发受到了严重阻碍。此前,我们证明了胶原杂交肽 [CHP,序列:(GPO),O:羟脯氨酸] 可以通过三螺旋形成特异性识别降解和展开的胶原链。在这里,我们展示了荧光标记的 CHP 可以在 3D 胶原培养物中,通过蛋白水解迁移的癌细胞的细胞周围基质周转,而无需使用合成荧光基质或基因修饰的细胞。为了便于体内成像,我们通过用(2S,4S)-4-氟脯氨酸(f)残基替换每个脯氨酸来修饰 CHP 序列,该残基干扰肽自身组装成同型三螺旋的固有倾向。我们表明,带有近红外荧光团的新型 CHP(GfO)能够对多发性骨髓瘤小鼠模型中的溶骨性骨病变进行体内成像和半定量评估。与传统技术(例如,微 CT)相比,基于 CHP 的成像在体外和体内都简单且多功能。因此,我们设想 CHP 在广泛的生物医学领域中的应用,从 ECM 生物学和药物效率的研究到临床分子成像的发展。